|
A randomised double-blind placebo-controlled, phase 3 study to assess the safety and efficacy of ART-123 in subjects with severe sepsis and coagulopathy
ART-123 is an investigational product known as 'Recombinant human soluble thrombomodulin'. Patients will be randomly assigned to receive ART-123 (0.06mg/kg/day, maximum 6mg/day) or placebo for 6 consecutive days. |
UPDATE:
Awaiting release of study results.
Awaiting release of study results.